Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for Vogt-Koyanagi-Harada disease
ChiCTR2000030147Phase 4Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in Vogt-Koyanagi-Harada disease (VKH), sponsored by Zhongshan Ophthalmic Center. Primary endpoints: Vision, Anterior uveitis activity and 3 more. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
03
Conditions
Vogt-Koyanagi-Harada disease (VKH)
Beyond the preview
Go deeper on ChiCTR2000030147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030147.